Colombia Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors. Could you introduce our readers to the…
Austria Günther Aschenbrenner, managing director of Théa Austria, a specialist French ophthalmology company, discusses the development of the company’s Austrian office since 2011 and how a strong portfolio acquired by Théa from Alcon has assisted them in growing rapidly. Furthermore, he provides an insight into the importance of long-term strategic thinking,…
Colombia Antonio Cordova, general manager of seca Latin America, shares the story of the recent establishment of the affiliate in Colombia that serves as a regional center for operations within Latin America. You were appointed general manager for Latin America a year and half ago; what was your assigned mission when…
Colombia Carlos Alberto Florez, newly appointed general manager of Aspen Colombia, already has a very clear view on Aspen’s strategic direction, discussing the expansion of the infant nutrition segment and the recent acquisition of anaesthetics lines. He also underlines his passion for start-up businesses and his eagerness to see Aspen evolve…
Canada Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed and modernized pharmaceutical framework agreement between industry and government, and the strong business case Canada needs to make in order…
Colombia Juan Carlos Mejia Hernandez, General Manager of Altadis Farmaceutica, a fresh entrant into the Colombian market, speaks about his strategies for advancing the educational system within the medical community by developing a platform based on digital channels. Mr. Mejia, Altadis Farmaceutica is a recent entrant to the Colombian market, having…
Canada Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends within the country. Lyndal, you established Ipsen’s Canadian affiliate in 2015. First and foremost, what opportunity did Ipsen globally see…
Austria Dr. Sabine Mӧritz-Kaisergruber and Helmut Kaisergruber, CEOs of Astro Pharma, a young vibrant Austrian pharmaceutical company, discuss their tailored strategy to establish themselves within the Austrian market as well as the importance of having a highly educated expert workforce. Furthermore, they highlight the reforms required to facilitate the nation’s biosimilar…
Austria Clemens Schödl, general manager of Gilead Austria, discusses Gilead’s footprint and reputation in Austria as the leading global player in HIV treatment and what must be done to bring Austrian innovation into a new era to fully leverage Gilead’s life changing treatments. As general manager, could you introduce our international…
Austria Siegfried Leitner, general manager of Accord Austria and Germany, and CEO and co-founder of A-med, provides an insight into the early years of his Accord affiliate and how it was able to establish itself in Austria and elaborates on the current portfolio of Accord in Austria. He also provides an…
Colombia Eduardo Obraczka, managing director at Merck Colombia, shares his appreciation for the flexibility of the Colombian talent pool, while explaining Merck’s successful strategy that has led to the impressive growth of the organization in the country, and highlights how Merck is continuously fostering an innovative and dynamic environment. How does…
Hong Kong Novartis Hong Kong general manager Dorine Leung and oncology head Sian Ng discuss the company’s restructuring, dividing the oncology business unit from the pharmaceutical division. In addition, they share their insights on what makes Hong Kong a destination for world-class clinical trials. Novartis recently underwent a major restructuring with the…
See our Cookie Privacy Policy Here